Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx plus cisplatin-based chemotherapy in locally advanced breast cancer
2006-006010-15Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jun 2007
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer, sponsored by European Institute of Oncology. Primary endpoints: Clinical response rate and Pathological complete remission rate. Started Jun 2007; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-006010-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006010-15.